Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.65 |
| ▸ | DRD4 | P21917 | 5/20 | 0.65 |
| ▸ | MC4R | P32245 | 3/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | BACE1 | P56817 | 2/20 | 0.59 |
| ▸ | BCHE | P06276 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.59 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15992138 | 1.00 | DRD2 (0.65) | DRD2DRD4MC4RSIGMAR1BACE1 | |
| SCHEMBL28409483 | 1.00 | DRD2 (0.65) | DRD2DRD4MC4RSIGMAR1BACE1 | |
| SCHEMBL239528 | 0.88 | DRD4 (0.71) | DRD2DRD4MC4RSIGMAR1BACE1 | |
| SCHEMBL239527 | 0.88 | DRD4 (0.71) | DRD2DRD4MC4RSIGMAR1BACE1 | |
| SCHEMBL20183285 | 0.87 | DRD4 (0.70) | DRD2DRD4MC4RSIGMAR1BACE1 | |
| SCHEMBL19614234 | 0.87 | DRD4 (0.70) | DRD2DRD4MC4RSIGMAR1BACE1 | |
| SCHEMBL17961749 | 0.87 | DRD4 (0.70) | DRD2DRD4MC4RSIGMAR1BACE1 | |
| SCHEMBL6378224 | 0.85 | CYP2C19 (0.70) | DRD2DRD4SIGMAR1DPP7 | |
| SCHEMBL7500995 | 0.84 | DRD4 (0.67) | DRD2DRD4SIGMAR1BACE1BCHE | |
| SCHEMBL1781392 | 0.84 | DRD4 (0.67) | DRD2DRD4SIGMAR1BACE1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137608-B | Janus kinase 1 selective inhibitor and pharmaceutical application thereof | 阳智化学（株） | 2020-06-19 | — | — | CN | disclosed |
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | YANG JI CHEMICAL CO., LTD. (KR) | 2019-09-10 | — | — | US | disclosed |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | YANG JI CHEMICAL CO., LTD. (KR) | 2018-08-23 | — | — | US | disclosed |
| EP-3327021-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | Yangji Chemical Co., Ltd. (KR) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407430-B2 | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | JAK1, JAK2, JAK3 | DRD2 4763/4885DRD4 4869/4885MC4R 1024/4885 |
| US-20180237440-A1 | JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF | JAK1, JAK2, JAK3 | DRD2 4676/4885DRD4 4819/4885MC4R 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.